[go: up one dir, main page]

DE3751362D1 - 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva. - Google Patents

5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.

Info

Publication number
DE3751362D1
DE3751362D1 DE3751362T DE3751362T DE3751362D1 DE 3751362 D1 DE3751362 D1 DE 3751362D1 DE 3751362 T DE3751362 T DE 3751362T DE 3751362 T DE3751362 T DE 3751362T DE 3751362 D1 DE3751362 D1 DE 3751362D1
Authority
DE
Germany
Prior art keywords
anticonvulsants
triazol
aryl
ones
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751362T
Other languages
English (en)
Other versions
DE3751362T2 (de
Inventor
Francis P Miller
John M Kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE3751362D1 publication Critical patent/DE3751362D1/de
Application granted granted Critical
Publication of DE3751362T2 publication Critical patent/DE3751362T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Photoreceptors In Electrophotography (AREA)
DE3751362T 1986-12-19 1987-12-17 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva. Expired - Fee Related DE3751362T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94463486A 1986-12-19 1986-12-19
US9031087A 1987-08-27 1987-08-27

Publications (2)

Publication Number Publication Date
DE3751362D1 true DE3751362D1 (de) 1995-07-27
DE3751362T2 DE3751362T2 (de) 1996-02-29

Family

ID=26782142

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751362T Expired - Fee Related DE3751362T2 (de) 1986-12-19 1987-12-17 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.

Country Status (10)

Country Link
EP (1) EP0273310B1 (de)
JP (1) JP2542880B2 (de)
KR (1) KR960003326B1 (de)
AT (1) ATE123942T1 (de)
DE (1) DE3751362T2 (de)
DK (1) DK172661B1 (de)
ES (1) ES2076141T3 (de)
GR (1) GR3017358T3 (de)
IE (1) IE66265B1 (de)
PH (1) PH24094A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4675959B2 (ja) 2004-07-27 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルトリアゾロン化合物
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
KR20090127178A (ko) 2007-03-29 2009-12-09 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
EP2935228B9 (de) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolonverbindungen und verwendungen davon
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1126882B (de) * 1960-05-03 1962-04-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 1,2,4-Triazolonen-(5)
BE621842A (de) * 1962-08-27
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
DD153953A3 (de) * 1980-04-01 1982-02-17 Gottfried Schuster Mittel zur chemotherapie von virosen der kulturpflanzen
DD160447A1 (de) * 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
AR243171A1 (es) * 1985-10-29 1993-07-30 Merrell Pharma Inc Procedimiento para preparar 5-aril-2,4-dialquil-3h-1,2,4-triazol-3-tionas.

Also Published As

Publication number Publication date
KR880007494A (ko) 1988-08-27
IE873458L (en) 1988-06-19
JPS63170313A (ja) 1988-07-14
JP2542880B2 (ja) 1996-10-09
EP0273310A2 (de) 1988-07-06
DK172661B1 (da) 1999-05-03
IE66265B1 (en) 1995-12-27
ES2076141T3 (es) 1995-11-01
DK671087D0 (da) 1987-12-18
ATE123942T1 (de) 1995-07-15
KR960003326B1 (ko) 1996-03-08
DK671087A (da) 1988-06-20
EP0273310A3 (de) 1991-01-09
GR3017358T3 (en) 1995-12-31
EP0273310B1 (de) 1995-06-21
PH24094A (en) 1990-03-05
DE3751362T2 (de) 1996-02-29

Similar Documents

Publication Publication Date Title
ATE45942T1 (de) Diarylacetylene, ihre herstellung und verwendung.
BR1100989A (pt) Composto e composição de matéria
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE68929540D1 (de) Substituierte Phenylpyrimidine Derivate, für die Behandlung oder Prevention von ZNS-Erkrankungen
ATE50763T1 (de) Tetralin-derivate, ihre herstellung und verwendung.
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE53377T1 (de) 1-substituierte tetralinderivate, ihre herstellung und verwendung.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE131056T1 (de) Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
FI873428A7 (fi) Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
DE3762879D1 (de) Polysulfurierte olefin-zusammensetzungen, ihre herstellung und ihre verwendung als schmiermittelzusaetze.
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
DE3576689D1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
DE69015411D1 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.
ATE157654T1 (de) Verwendung von aminoalkyl-substituierten 5,6- dihydro-dibenz(b,e)azepin-6,11-dion-11-oximen als antivirale mittel
ATE66218T1 (de) 5-heterocyclisch substituierte-3h-1,2,4-triazol-3-thione und ihre verwendung als antidepressiva.
ATE72112T1 (de) Verwendung von 1-benzyl-amino-alkylpyrrolidinonen als antidepressiva.
DE3777432D1 (de) Verwendung von 2-aminoalkyl-5-pyridinol-verbindungen als nootropika und antidepressiva.
ATE30032T1 (de) N-acylderivate von dipeptiden, ihre herstellung und verwendung bei der therapie von krankheiten und mittel dafuer.
ATE78466T1 (de) 3-phenyl-2-styryl-pyrrolidine, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee